STAT3 and aggressive NK-cell leukemia: They tested the drugs that could target STAT3 activity using different cell model systems (Ba/F3 cells, NK cell leukemia/lymphoma cells, and LGL leukemia patient samples) and identified four classes of drugs, among 306 approved compounds, that seemed to be effective against wild type STAT3 and its mutated isoforms, i.e., mTOR, JAK, Hsp90 and CDK inhibitors.